Digital therapeutics have been plodding on a steady path toward acceptance within healthcare, but the modality reached new heights during a year of unprecedented adoption for digital health technologies. More and more software-based treatments are picking up regulatory approvals – including three De Novo clearances in 2020 alone – while the ongoing COVID-19 pandemic has exposed more consumers,...
Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira's digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.
In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from...
The alarming scale of the opioid use disorder (OUD) epidemic has resulted in unprecedented human and economic devastation, and there is significant opportunity for digital tools to alter the gold standard of care to one that is ongoing and on-demand.
The epidemic has only worsened since the onset of COVID-19, given heightened economic instability, social isolation, disruption to transportation...
23andMe's new COVID-19 resource. Consumer genomics company 23andMe has released a new interactive tool that allows users to see how various health factors could impact the risk of COVID-19 hospitalization. The COVID-19 Severity Calculator pulls data from the company's COVID-19 study, which included 10,000 participants diagnosed with the disease and 750 who were hospitalized.
23andMe warned that...
Clinical trials have become big news this year amid the search for COVID-19 vaccines and treatments. They are a critical component of helping the FDA validate that new drugs and diagnostics will be both safe and effective.
Pharmaceutical companies spend over $45B a year running clinical trials, which are, by design, very methodical and measured. Unfortunately, they are also slow, unpredictable...
Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry.
“Here we are talking about how can we bring this to pharma... we are going to...
Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture.
The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
Biogen has announced a new multiyear research study on cognitive decline that will be conducted using the Apple Watch and iPhone.
The observational study is being conducted in collaboration with Apple, according to the announcement, and is set to kick off later this year. The project's primary goal is to establish digital biomarkers for monitoring long-term cognitive performance and to spot early...
.jpeg?itok=HF3iI7dj "Person answering their front door and getting a delivery from another person")
